Real-World check: does the CLL drug acalabrutinib live up to trial hype?
NCT ID NCT05437250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) when used in regular hospitals, not just in clinical trials. Researchers will track 350 patients in France for about 3 years to see how long they stay on the drug and why they might stop. The goal is to understand real-world benefits and challenges, without giving any new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Aix-en-Provence, France
-
Research Site
Amiens, France
-
Research Site
Angers, France
-
Research Site
Ars-Laquenexy, France
-
Research Site
Avignon, France
-
Research Site
Besançon, France
-
Research Site
Béziers, France
-
Research Site
Bobigny, France
-
Research Site
Bourg-en-Bresse, France
-
Research Site
Brest, France
-
Research Site
Caen, France
-
Research Site
Cahors, France
-
Research Site
Carcassonne, France
-
Research Site
Cesson-Sévigné, France
-
Research Site
Chalon-sur-Saône, France
-
Research Site
Chambéry, France
-
Research Site
Clamart, France
-
Research Site
Clermont-Ferrand, France
-
Research Site
Corbeil-Essonnes, France
-
Research Site
Dunkirk, France
-
Research Site
Essey-lès-Nancy, France
-
Research Site
Grenoble, France
-
Research Site
La Chaussée-Saint-Victor, France
-
Research Site
La Tronche, France
-
Research Site
LE Chesnay-rocquencourt, France
-
Research Site
Le Kremlin-Bicêtre, France
-
Research Site
Le Mans, France
-
Research Site
Le Puy-en-Velay, France
-
Research Site
Lens, France
-
Research Site
Libourne, France
-
Research Site
Lille, France
-
Research Site
Limoges, France
-
Research Site
Lorient, France
-
Research Site
Marseille, France
-
Research Site
Meaux, France
-
Research Site
Melun, France
-
Research Site
Mont-de-Marsan, France
-
Research Site
Nantes, France
-
Research Site
Nevers, France
-
Research Site
Nîmes, France
-
Research Site
Orléans, France
-
Research Site
Paris, France
-
Research Site
Perpignan, France
-
Research Site
Pessac, France
-
Research Site
Périgueux, France
-
Research Site
Pontoise, France
-
Research Site
Reims, France
-
Research Site
Rennes, France
-
Research Site
Roubaix, France
-
Research Site
Rouen, France
-
Research Site
Saumur, France
-
Research Site
Tarbes, France
-
Research Site
Toulouse, France
-
Research Site
Tours, France
-
Research Site
Trévenans, France
-
Research Site
Troyes, France
-
Research Site
Valence, France
-
Research Site
Vandœuvre-lès-Nancy, France
-
Research Site
Vantoux, France
-
Research Site
Vesoul, France
-
Research Site
Vichy, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?